1[1]Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med, 2000, 343:938-952.
2[2]Hooper DC, Bagasra O, Marini JC, et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite:implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA, 1997, 94:2528-2533.
3[3]Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA, 1998, 95:675-680.
4[4]Drulovic J, Dujmovic I, Stojsavljevic N, et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol, 2001, 248:121-126.
5[5]Toncev G, Milicic B, Toncev S, et al. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and bloodbrain harrier dvsfunction. Eur J Neurol, 2002, 9:221-226.
6[7]Knapp CM, Constantinescu CS, Tan JH, et al. Serum uric acid levels in optic neuritis. Mult Scler, 2004, 10:278-280.
8[9]Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler, 2000, 6:378-381.
9[10]Galboiz Y, Miller A. Immunological indicators of disease activity and prognosis in multiple sclerosis. Curr Opin Neurol, 2002, 15:233-237.
10[11]Spitsin S, Hooper DC, Leist T, et al. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler,2001, 7:313-319.
